**GSK’s Arexvy RSV Vaccine Approved for Broader Adult Use by European Regulators**
Key Takeaways:
- GSK’s RSV vaccine, Arexvy, receives positive CHMP opinion for adults 18 and older
- The updated recommendation expands access beyond adults aged 60+
- Regulatory decision from the European Commission expected in coming months
London — RSV is trending after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on **GSK’s** Arexvy vaccine for **expanded use in adults aged 18 and up**, especially those at higher risk of severe respiratory syncytial virus (RSV) disease. This marks a significant regulatory step in RSV prevention as Arexvy was previously approved only for adults aged 60 years and older.
Broader Access to Protection Against RSV
The CHMP’s recommendation, announced on **April 26, 2024**, paves the way for the **European Commission to grant marketing authorization** for the updated indication in the coming months. The expanded label is based on data showing the vaccine’s safety and immune response in younger adults with underlying conditions that place them at increased risk of severe RSV infection. **GSK** stated that the vaccine demonstrated an acceptable safety profile across age groups.
Why RSV Vaccination Is a Rising Priority
This development comes as health authorities across Europe and globally focus on reducing the burden of RSV, a highly contagious respiratory virus that causes serious illness in older adults and those with chronic conditions. Historically, RSV has been mainly associated with infants, but in recent years its impact on adults has gained broader recognition. The CHMP’s expanded view of at-risk populations signals **growing urgency to mitigate hospitalizations and complications** linked to seasonal RSV outbreaks. According to GSK, an estimated **16 million adults in the EU** are at increased risk due to underlying health issues.
Potential Impact on Public Health and GSK Business
If approved by the European Commission, this expanded use of Arexvy could substantially increase **vaccine uptake** and strengthen GSK’s foothold in the respiratory vaccine market. Arexvy was the **first RSV vaccine approved for adults globally**, gaining FDA approval in the U.S. in 2023. GSK is positioning the shot as a seasonal vaccine for populations vulnerable to severe RSV infections. Wider access could also pressure other RSV vaccine developers, including **Pfizer** and **Moderna**, to pursue label expansions. Reimbursement decisions and national vaccination plans will determine the scale of the rollout across EU countries.
Frequently Asked Questions
Q: Why is rsv trending?
A: GSK’s Arexvy RSV vaccine received a positive CHMP opinion for use in all adults aged 18 and older, expanding beyond its current approval for those 60+.
Q: What happens next?
A: The European Commission will make a final decision on regulatory approval in the coming months, potentially allowing an EU-wide rollout for expanded adult use.
#RSVvaccine #GSK #Arexvy #HealthNews #EMAapproval
